Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD Market Closed
Market Cap: 242.3m AUD
Have any thoughts about
Probiotec Ltd?
Write Note

P/E
Price to Earnings

27.9
Current
20.6
Median
21.4
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
27.9
=
Market Cap
242.3m AUD
/
Net Income
8.7m AUD
All Countries
Close
Market Cap P/E
AU
Probiotec Ltd
ASX:PBP
242.3m AUD 27.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
734.5B USD 87.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 28.6
US
Johnson & Johnson
NYSE:JNJ
352B USD 24
US
Merck & Co Inc
NYSE:MRK
255.8B USD 21.1
CH
Roche Holding AG
SIX:ROG
211.7B CHF 18.4
UK
AstraZeneca PLC
LSE:AZN
165.4B GBP 32.1
CH
Novartis AG
SIX:NOVN
177.1B CHF 11.1
US
Pfizer Inc
NYSE:PFE
153.7B USD 36.2
Earnings Growth PEG
AU
Probiotec Ltd
ASX:PBP
Average P/E: 31.9
27.9
20%
1.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.8
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.6
23%
1.2
US
Johnson & Johnson
NYSE:JNJ
24
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
21.1
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.4
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.1
40%
0.8
CH
Novartis AG
SIX:NOVN
11.1
9%
1.2
US
Pfizer Inc
NYSE:PFE
36.2
102%
0.4

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
16.4
2-Years Forward
P/E
14.8
3-Years Forward
P/E
12.8